… Therefore, concerns about the recurrence of symptoms should not be a reason to avoid
using ritonavir-boosted nirmatrelvir. Although insufficient drug exposure by individual …

… (nirmatrelvir/ritonavir) on patient outcomes and healthcare resource utilization (HCRU). We
also intend to assess the comparability of the patients who were treated with Paxlovid versus …

… We read with interest the recent meta-analysis assessing the clinical efficacy and safety of
nirmatrelvir plus ritonavir (NMV-r) in the treatment of patients with COVID-19. Based on the …

… This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in treating
patients with coronavirus disease-2019 (COVID-19) and substance use disorders (SUDs). This …

… Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir (NMV-r)
in high-risk nonhospitalized unvaccinated patients reduced the risk of progression to severe …

… therapy for patients unable to receive intravenous remdesivir or oral nirmatrelvir-ritonavir [1]. …
We compare their outcomes with those in patients treated with ritonavir-boosted nirmatrelvir, …

… In addition to the baseline policy of treating nobody with nirmatrelvir/ritonavir, we
considered 4 increasingly expansive eligibility policies for persons with confirmed SARS-CoV-2 …

… nirmatrelvir and ritonavir in human plasma and nirmatrelvir in human urine were validated
at York Bioanalytical Solutions (York, UK). The calibration curve range for the plasma method …

… A recent success in the latter group is nirmatrelvir/ritonavir (… inhibitor, PF-07321332;
nirmatrelvir/ritonavir (Paxlovid ® ) in … ) for the oral antiviral drug, nirmatrelvir/ritonavir (Paxlovid ® ), …

… this current study received concomitant treatment with remdesivir plus nirmatrelvir/ritonavir. …
or nirmatrelvir/ritonavir during the Omicron SARS-CoV-2 period. Nirmatrelvir/ritonavir was …